| Spread | 0.40 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 97.96 |
| Open* | 97.96 |
| 1-Year Change* | -39.32% |
| Day's Range* | 97.96 - 101.46 |
| 52 wk Range | 88.00-188.99 |
| Average Volume (10 days) | 405.14K |
| Average Volume (3 months) | 13.98M |
| Market Cap | 23.10B |
| P/E Ratio | 7.92 |
| Shares Outstanding | 237.72M |
| Revenue | 7.22B |
| EPS | 12.26 |
| Dividend (Yield %) | N/A |
| Beta | 0.25 |
| Next Earnings Date | Mar 25, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 28, 2023 | 98.25 | 2.13 | 2.22% | 96.12 | 98.70 | 95.72 |
| Nov 27, 2023 | 96.36 | -2.37 | -2.40% | 98.73 | 99.71 | 96.36 |
| Nov 24, 2023 | 98.58 | 1.30 | 1.34% | 97.28 | 99.97 | 96.60 |
| Nov 22, 2023 | 97.59 | 0.66 | 0.68% | 96.93 | 98.19 | 95.65 |
| Nov 21, 2023 | 96.74 | -1.32 | -1.35% | 98.06 | 99.45 | 95.19 |
| Nov 20, 2023 | 98.61 | -0.28 | -0.28% | 98.89 | 99.60 | 98.24 |
| Nov 17, 2023 | 99.25 | -0.27 | -0.27% | 99.52 | 100.64 | 98.55 |
| Nov 16, 2023 | 99.83 | -0.16 | -0.16% | 99.99 | 100.31 | 98.11 |
| Nov 15, 2023 | 100.47 | -0.08 | -0.08% | 100.55 | 102.13 | 98.58 |
| Nov 14, 2023 | 100.55 | 2.66 | 2.72% | 97.89 | 101.59 | 96.69 |
| Nov 13, 2023 | 97.78 | -1.00 | -1.01% | 98.78 | 99.35 | 96.16 |
| Nov 10, 2023 | 99.13 | 0.59 | 0.60% | 98.54 | 100.46 | 97.56 |
| Nov 9, 2023 | 98.67 | 0.16 | 0.16% | 98.51 | 100.06 | 97.54 |
| Nov 8, 2023 | 99.57 | -2.26 | -2.22% | 101.83 | 102.40 | 98.64 |
| Nov 7, 2023 | 101.73 | 2.13 | 2.14% | 99.60 | 102.36 | 97.05 |
| Nov 6, 2023 | 99.63 | 3.73 | 3.89% | 95.90 | 104.13 | 95.61 |
| Nov 3, 2023 | 94.95 | 2.77 | 3.00% | 92.18 | 98.17 | 91.78 |
| Nov 2, 2023 | 92.45 | -0.97 | -1.04% | 93.42 | 94.28 | 88.61 |
| Nov 1, 2023 | 92.95 | -0.26 | -0.28% | 93.21 | 94.74 | 92.17 |
| Oct 31, 2023 | 93.76 | 0.57 | 0.61% | 93.19 | 94.14 | 90.97 |
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, March 25, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q4 2023 BioNTech SE Earnings Release Q4 2023 BioNTech SE Earnings ReleaseForecast -Previous - |
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 17310.6 | 18976.7 | 482.325 | 108.589 | 127.575 |
| Revenue | 17310.6 | 18976.7 | 482.325 | 108.589 | 127.575 |
| Cost of Revenue, Total | 2995 | 2911.5 | 59.333 | 17.361 | 13.69 |
| Gross Profit | 14315.6 | 16065.2 | 422.992 | 91.228 | 113.885 |
| Total Operating Expense | 4667.9 | 3692.9 | 564.742 | 290.107 | 181.429 |
| Selling/General/Admin. Expenses, Total | 544.2 | 328.9 | 103.457 | 44.45 | 27.07 |
| Research & Development | 1487.7 | 916.3 | 614.837 | 197.893 | 124.728 |
| Depreciation / Amortization | 49.3 | 40.2 | 35.296 | 32.388 | 20.617 |
| Unusual Expense (Income) | -1.4 | -137.2 | 0 | ||
| Other Operating Expenses, Total | -65 | -1.1 | -248.181 | -1.985 | -4.676 |
| Operating Income | 12642.7 | 15283.8 | -82.417 | -181.518 | -53.854 |
| Interest Income (Expense), Net Non-Operating | 314.1 | -215.5 | -60.337 | 2.404 | 6.24 |
| Other, Net | -2.7 | -21.9 | -3.048 | -0.326 | -0.048 |
| Net Income Before Taxes | 12954.1 | 15046.4 | -145.802 | -179.44 | -47.662 |
| Net Income After Taxes | 9434.4 | 10292.5 | 15.198 | -179.172 | -48.262 |
| Minority Interest | 0 | 0.116 | 0.243 | ||
| Net Income Before Extra. Items | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Net Income | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Income Available to Common Excl. Extra. Items | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Income Available to Common Incl. Extra. Items | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Diluted Net Income | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Diluted Weighted Average Shares | 249.8 | 259.7 | 253.3 | 210.654 | 226.262 |
| Diluted EPS Excluding Extraordinary Items | 37.7678 | 39.6323 | 0.06 | -0.85 | -0.21223 |
| Diluted Normalized EPS | 37.7637 | 39.2709 | 0.06 | -0.85 | -0.21223 |
| Interest Expense (Income) - Net Operating | -341.9 | -365.7 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 167.7 | 1277 | 4278.3 | 3461.2 | 3196.5 |
| Revenue | 167.7 | 1277 | 4278.3 | 3461.2 | 3196.5 |
| Cost of Revenue, Total | 162.9 | 96 | 183.5 | 752.8 | 764.6 |
| Gross Profit | 4.8 | 1181 | 4094.8 | 2708.4 | 2431.9 |
| Total Operating Expense | 731 | 622.6 | 985.4 | 1073.7 | 986.9 |
| Selling/General/Admin. Expenses, Total | 140.8 | 131.6 | 137.5 | 153.8 | 147.8 |
| Research & Development | 359.6 | 319.3 | 496.5 | 328.2 | 388 |
| Depreciation / Amortization | 13.8 | 14.7 | 13.3 | 13.6 | 11.6 |
| Interest Expense (Income) - Net Operating | 58.6 | 74.6 | 166.5 | -166.4 | -287.3 |
| Unusual Expense (Income) | -1.2 | -0.2 | 0 | ||
| Other Operating Expenses, Total | -4.7 | -13.6 | -10.7 | -8.1 | -37.8 |
| Operating Income | -563.3 | 654.4 | 3292.9 | 2387.5 | 2209.6 |
| Interest Income (Expense), Net Non-Operating | 152.4 | 53.2 | -120.3 | 56.7 | 109.7 |
| Other, Net | -1.3 | 0.1 | 0 | -0.1 | 0 |
| Net Income Before Taxes | -412.2 | 707.7 | 3172.6 | 2444.1 | 2319.3 |
| Net Income After Taxes | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Net Income Before Extra. Items | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Net Income | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Income Available to Common Excl. Extra. Items | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Income Available to Common Incl. Extra. Items | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Diluted Net Income | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Diluted Weighted Average Shares | 241.013 | 244.97 | 244.761 | 255.716 | 259.225 |
| Diluted EPS Excluding Extraordinary Items | -0.79 | 2.05005 | 9.3099 | 6.98 | 6.45 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.79 | 2.05005 | 9.30638 | 6.97943 | 6.45 |
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 21922 | 15072.3 | 1666.9 | 560.151 | 448.961 |
| Cash and Short Term Investments | 14064.5 | 2074.3 | 1347.44 | 520.829 | 411.831 |
| Cash | 13875.1 | 1692.7 | 1210.21 | 519.149 | 411.495 |
| Short Term Investments | 189.4 | 381.6 | 137.234 | 1.68 | 0.336 |
| Total Receivables, Net | 7146 | 12382.1 | 170.521 | 20.205 | 28.44 |
| Accounts Receivable - Trade, Net | 7145.6 | 12381.7 | 165.468 | 11.913 | 18.938 |
| Total Inventory | 439.6 | 502.5 | 64.12 | 11.722 | 5.789 |
| Prepaid Expenses | 29.845 | 0.351 | 0.155 | ||
| Other Current Assets, Total | 271.9 | 113.4 | 54.967 | 7.044 | 2.746 |
| Total Assets | 23279.1 | 15830.8 | 2318.62 | 797.647 | 652.986 |
| Property/Plant/Equipment, Total - Net | 821.1 | 520.4 | 325.956 | 148.062 | 115.965 |
| Property/Plant/Equipment, Total - Gross | 937.4 | 594.6 | 384.288 | 197.345 | 152.617 |
| Accumulated Depreciation, Total | -116.3 | -74.2 | -58.332 | -49.285 | -36.652 |
| Goodwill, Net | 61.2 | 57.8 | 53.697 | 2.978 | 0.534 |
| Intangibles, Net | 158.5 | 144.6 | 109.793 | 86.456 | 87.508 |
| Long Term Investments | 80.2 | 21.3 | 0 | 0.018 | |
| Other Long Term Assets, Total | 236.1 | 14.4 | 162.278 | 0 | |
| Total Current Liabilities | 2950.6 | 3481.6 | 606.014 | 138.142 | 126.121 |
| Accounts Payable | 204.1 | 160 | 102.288 | 20.498 | 41.721 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 36 | 129.9 | 6.127 | 3.485 | 8.266 |
| Other Current Liabilities, Total | 2710.5 | 3191.7 | 497.599 | 114.159 | 76.134 |
| Total Liabilities | 3223.5 | 3937.1 | 946.774 | 304.155 | 386.833 |
| Total Long Term Debt | 176.2 | 171.6 | 231.047 | 68.904 | 5.6 |
| Long Term Debt | 2.1 | 17.9 | 153.016 | 14.777 | 5.6 |
| Minority Interest | 0 | 0.847 | |||
| Other Liabilities, Total | 90.5 | 217.2 | 109.432 | 97.109 | 254.265 |
| Total Equity | 20055.6 | 11893.7 | 1371.85 | 493.492 | 266.153 |
| Common Stock | 248.6 | 246.3 | 246.31 | 232.304 | 193.296 |
| Retained Earnings (Accumulated Deficit) | 19812.3 | 11651.2 | 1130.32 | 266.713 | 72.857 |
| Total Liabilities & Shareholders’ Equity | 23279.1 | 15830.8 | 2318.62 | 797.647 | 652.986 |
| Total Common Shares Outstanding | 243.215 | 242.521 | 241.521 | 226.78 | 226.262 |
| Capital Lease Obligations | 174.1 | 153.7 | 78.031 | 54.127 | |
| Treasury Stock - Common | -5.3 | -3.8 | -4.789 | -5.525 | |
| Deferred Income Tax | 6.2 | 66.7 | 0.281 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 18749.1 | 19213.9 | 20086.1 | 21922 | 21268.8 |
| Cash and Short Term Investments | 15749.1 | 15557.3 | 12501.9 | 14064.5 | 13428.5 |
| Cash | 13495.8 | 14166.6 | 12143.9 | 13875.1 | 13423.7 |
| Short Term Investments | 2253.3 | 1390.7 | 358 | 189.4 | 4.8 |
| Total Receivables, Net | 2298.1 | 2995.4 | 6988.8 | 7146 | 7309.8 |
| Accounts Receivable - Trade, Net | 2008.8 | 2663.8 | 6456.2 | 7145.6 | 7309.4 |
| Total Inventory | 415.7 | 448.9 | 424.1 | 439.6 | 294.8 |
| Other Current Assets, Total | 286.2 | 212.3 | 171.3 | 271.9 | 235.7 |
| Total Assets | 22207.2 | 22225.6 | 22079 | 23279.1 | 22660.6 |
| Property/Plant/Equipment, Total - Net | 925.9 | 894 | 847.6 | 821.1 | 760.5 |
| Intangibles, Net | 665.5 | 501.4 | 378.6 | 219.7 | 226.2 |
| Other Long Term Assets, Total | 208.4 | 242 | 249.9 | 236.1 | 352.3 |
| Total Current Liabilities | 1807.2 | 1819 | 1550.9 | 2950.6 | 3957.7 |
| Accounts Payable | 222.7 | 228.6 | 29.9 | 204.1 | 296.5 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 40 | 38.6 | 37.4 | 36 | 37 |
| Other Current Liabilities, Total | 1544.5 | 1551.8 | 1483.6 | 2710.5 | 3624.2 |
| Total Liabilities | 2340.4 | 2319.1 | 1813.7 | 3223.5 | 4294.3 |
| Total Long Term Debt | 161.9 | 167.1 | 172.4 | 176.2 | 237 |
| Long Term Debt | 161.9 | 167.1 | 172.4 | 176.2 | 237 |
| Deferred Income Tax | 43.1 | 4.5 | 5.3 | 6.2 | 7 |
| Other Liabilities, Total | 328.2 | 328.5 | 85.1 | 90.5 | 92.6 |
| Total Equity | 19866.8 | 19906.5 | 20265.3 | 20055.6 | 18366.3 |
| Common Stock | 248.6 | 248.6 | 248.6 | 248.6 | 248.6 |
| Retained Earnings (Accumulated Deficit) | 19629 | 19666.7 | 20024.3 | 19812.3 | 18128 |
| Treasury Stock - Common | -10.8 | -8.8 | -7.6 | -5.3 | -10.3 |
| Total Liabilities & Shareholders’ Equity | 22207.2 | 22225.6 | 22079 | 23279.1 | 22660.6 |
| Total Common Shares Outstanding | 237.715 | 239.771 | 240.99 | 243.215 | 242.521 |
| Long Term Investments | 1292.7 | 1374.3 | 516.8 | 80.2 | 52.8 |
| Goodwill, Net | 365.6 |
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 12954.1 | 15046.4 | -145.802 | -179.44 | -47.662 |
| Cash From Operating Activities | 13577.4 | 889.7 | -13.474 | -198.537 | -58.877 |
| Cash From Operating Activities | 123.3 | 75.2 | 38.744 | 33.896 | 21.984 |
| Non-Cash Items | 247.6 | -32.6 | 188.487 | 31.109 | 7.943 |
| Cash Taxes Paid | 4222.1 | 3457.9 | -0.378 | -0.122 | 0.304 |
| Cash Interest Paid | 21.5 | 12.2 | 3.628 | 2.044 | 1.769 |
| Changes in Working Capital | 252.4 | -14199.3 | -94.903 | -84.102 | -41.142 |
| Cash From Investing Activities | -35.3 | -566.1 | -144.848 | -77.115 | -66.452 |
| Capital Expenditures | -363.3 | -154 | -85.446 | -71.08 | -67.157 |
| Other Investing Cash Flow Items, Total | 328 | -412.1 | -59.402 | -6.035 | 0.705 |
| Cash From Financing Activities | -1419.3 | 94.2 | 894.725 | 383.29 | 365.177 |
| Issuance (Retirement) of Stock, Net | -875.9 | 160.9 | 753.007 | 375.351 | 361.725 |
| Issuance (Retirement) of Debt, Net | -59.1 | -66.7 | 141.718 | 7.939 | 3.452 |
| Foreign Exchange Effects | 59.6 | 64.7 | -45.343 | 0.016 | -0.459 |
| Net Change in Cash | 12182.4 | 482.5 | 691.06 | 107.654 | 239.389 |
| Total Cash Dividends Paid | -484.3 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 707.7 | 12954.1 | 9781.5 | 7337.4 | 5018.1 |
| Cash From Operating Activities | -677.4 | 13577.4 | 12748.2 | 7969.3 | 4050.2 |
| Cash From Operating Activities | 31.4 | 123.3 | 94.3 | 60.8 | 27.6 |
| Non-Cash Items | 54 | 247.6 | -267.6 | -438 | -197 |
| Cash Taxes Paid | 844.9 | 4222.1 | 2834.7 | 2081.4 | 1290 |
| Cash Interest Paid | 1.2 | 21.5 | 16.5 | 12.2 | 6.4 |
| Changes in Working Capital | -1470.5 | 252.4 | 3140 | 1009.1 | -798.5 |
| Cash From Investing Activities | -735.4 | -35.3 | 125.7 | 209 | 287.4 |
| Capital Expenditures | -54.8 | -363.3 | -218.8 | -136.2 | -60.8 |
| Other Investing Cash Flow Items, Total | -680.6 | 328 | 344.5 | 345.2 | 348.2 |
| Cash From Financing Activities | -291.3 | -1419.3 | -1354.6 | -701.2 | 80.3 |
| Issuance (Retirement) of Debt, Net | -9.3 | -59.1 | -50.1 | -40.5 | -30.2 |
| Foreign Exchange Effects | -27.1 | 59.6 | 211.7 | 165 | 53.5 |
| Net Change in Cash | -1731.2 | 12182.4 | 11731 | 7642.1 | 4471.4 |
| Issuance (Retirement) of Stock, Net | -282 | -875.9 | -820.2 | -176.4 | 110.5 |
| Total Cash Dividends Paid | -484.3 | -484.3 | -484.3 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| AT Impf GmbH | Corporation | 44.0475 | 105613143 | -501758 | 2022-12-31 | |
| Medine GmbH | Corporation | 17.2689 | 41405853 | -100000 | 2022-12-31 | |
| Baillie Gifford & Co. | Investment Advisor | 3.1073 | 7450298 | -90614 | 2023-06-30 | LOW |
| PRIMECAP Management Company | Investment Advisor | 1.9435 | 4659853 | 85590 | 2023-06-30 | |
| Temasek Holdings Pte. Ltd. | Sovereign Wealth Fund | 1.8843 | 4518080 | 140058 | 2023-06-30 | LOW |
| Flossbach von Storch AG | Investment Advisor | 1.4652 | 3513215 | 71468 | 2023-09-30 | LOW |
| Sahin (Ugur MD) | Individual Investor | 1.314 | 3150649 | 3150649 | 2022-12-31 | |
| Huber (Christoph M.D.) | Individual Investor | 1.0898 | 2613019 | 610979 | 2022-12-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 0.8468 | 2030282 | -580576 | 2023-06-30 | LOW |
| Wolfgang (Jeggle Helmut) | Individual Investor | 0.6364 | 1525967 | -400000 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6087 | 1459453 | -3569 | 2023-06-30 | LOW |
| Marett (Sean) | Individual Investor | 0.3913 | 938140 | 232204 | 2022-12-31 | LOW |
| Capital World Investors | Investment Advisor | 0.3857 | 924680 | -466048 | 2023-06-30 | LOW |
| Tureci (Ozlem) | Individual Investor | 0.3809 | 913247 | 913247 | 2022-12-31 | |
| Poetting (Sierk) | Individual Investor | 0.3085 | 739784 | 213722 | 2022-12-31 | LOW |
| Altrinsic Global Advisors, LLC | Investment Advisor/Hedge Fund | 0.2954 | 708393 | 159498 | 2023-06-30 | LOW |
| ACATIS Investment Kapitalverwaltungsgesellschaft GmbH | Investment Advisor | 0.293 | 702592 | 0 | 2023-08-31 | LOW |
| Baillie Gifford Overseas Ltd. | Investment Advisor | 0.2568 | 615712 | 37283 | 2023-08-31 | LOW |
| DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.2246 | 538522 | -31992 | 2023-06-30 | LOW |
| Gilder Gagnon Howe & Co. LLC | Hedge Fund | 0.1928 | 462278 | 6422 | 2023-06-30 | LOW |
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Founded in 2008, BioNTech is an innovative biotechnology company from Germany, specialising in the research, development and producing of active individualised immunotherapies. The company adheres to a patient-specific approach to treatment of serious diseases, such as cancer.
BioNTech shares a vision that every patient’s tumour is unique. It means that each patient’s treatment should be individualised. To implement the scientists’ ideas into practice, BioNTech has developed pioneering therapeutics for cancer and other rare and infectious diseases.
Headquartered in Mainz, Germany, the company is aimed at becoming the world’s leading biotechnology company for individialised cancer treatment. By 2020, BioNTech had more than 440 patients treated across 17 tumour types. The company has more than 1,300 employees and seven pharmaceutical partners.
In August 2018, the company partnered with the US pharmaceutical giant Pfizer Inc to develop mRNA-based vaccines for preventing influenza. In September 2019, BioNTech started working on the development of tuberculosis and HIV programmes and preclinical vaccine and immunotherapy candidates for the prevention of tuberculosis and HIV infections under an agreement with the Bill & Melinda Gates Foundation.
BioNTech stock floated on the NASDAQ stock exchange through a $150m initial public offering (IPO) in October 2019. Since then the BNTX stock quote has been traded on the US market.
In November 2020, BioNTech and Pfizer triggered the strongest wave of optimism on the stock market after they announced that their Covid-19 vaccine showed 90 per cent effectiveness during the phase-three clinical trials. The BioNTech share price soared 14 per cent the day after the announcement.
In 2019, BioNTech reported total revenues of about €109m. According to the estimates from Morgan Stanley, BioNTech and Pfizer can make around $13bn from vaccine sales, getting $6.5bn each if these estimates are correct.
Looking closely at the BioNTech stock price chart in 2020, we can see that BNTX stock has been trading in a range of $18.60-$115. Since the large sell-off in March 2020, the BioNTech SE (BNTX) stock quote grew from $28.55 on March 12, 2020, to $112.76 on November 10, 2020, which is a growth of 294 per cent.
Follow the BioNTech share price live on our interactive share price chart and build your own forecast for the famous German biotechnology company. Follow the latest BioNTech share news and spot the best levels to open profitable CFD trades at Capital.com.
| Industry: | Bio Therapeutic Drugs |
An der Goldgrube 12
MAINZ
RHEINLAND-PFALZ 55131
DE
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023Invest in BioNTech shares, other major stocks, indices, forex, commodities and cryptocurrencies with CFDs at Capital.com’s award-winning platform. No commission. FCA and CySEC regulated. Available on web and mobile. AI technology.
Learn more about BioNtech SE
Join the 570.000+ traders worldwide that chose to trade with Capital.com
